On September 1, 2026, the U.S. House of Representatives voted 370–48 to concur in the Senate’s amendments to H.R. 6500, the Continuing Appropriations and Extensions Act, 2027. The bill funds the federal government through December 11, 2026, and—critically for the hemp and cannabis industries—delays the effective date of most of the restrictive new federal hemp-product definitions enacted last November from November 12 to December 11, 2026. As of September 2, the bill has been presented to the President. The White House’s August 3 Statement of Administration Policy expressed support for the Senate amendment, and senior advisers indicated they would recommend the President sign it.
The one-month reprieve is narrow in scope and short in duration, but it arrives at a pivotal moment. It gives Congress a compressed window to replace outright prohibition with a federal regulatory framework.
- The 2018 Farm Bill, the 2025 Redefinition, and the Proposed Delay
The 2018 Farm Bill removed hemp from the Controlled Substances Act’s definition of marijuana, defining it as Cannabis sativa L. and its derivatives containing no more than 0.3% delta-9 THC on a dry-weight basis. Because the definition focused on delta-9 THC, products containing other intoxicating cannabinoids—including delta-8 THC—entered the market while remaining federally classified as hemp.
Congress substantially narrowed that definition in November 2025. Beginning November 12, 2026, the law generally measures total THC, including THC-A, and excludes certain products from the definition of hemp. Those exclusions include final products containing more than 0.4 milligrams of total THC and similarly acting cannabinoids per container, certain intermediate products, and products containing synthetic or otherwise non-naturally produced cannabinoids. Products falling outside the revised definition would be treated as marijuana under the CSA, with significant consequences for their manufacture, distribution, and interstate sale. Industrial hemp remains expressly protected.
The proposed delay emerged from a broader regulatory debate over whether hemp-derived cannabinoid products should be prohibited or regulated. The White House, hemp and beverage-industry groups, farmers, and bipartisan congressional majorities supported the extension to allow time to develop standards addressing testing, labeling, potency, age restrictions, and consumer safety. Opponents—including a bipartisan coalition of 35 attorneys general, state-regulated marijuana-industry groups, public-health and anti-legalization organizations, and some lawmakers—argued that delaying the new definition would prolong an inadequately regulated market, increase youth access, undermine state cannabis programs, and create further regulatory uncertainty.
- What H.R. 6500 Does—and Does Not—Delay
H.R. 6500 delays the effective date of most of the 2025 hemp-definition changes from November 12, 2026 to December 11, 2026—the same date the continuing resolution’s government funding authority expires.
The delay is not blanket. It does not extend to intermediate or final products containing cannabinoids “that are not capable of being naturally produced by a Cannabis sativa L. plant.” That exclusion remains scheduled to take effect on November 12, 2026, and products falling within it would be classified as marijuana under the CSA. Other changes to the federal hemp definition would generally be delayed until December 11, 2026.
In practical terms, the delay, if enacted, preserves the current federal legal status of naturally derived hemp-cannabinoid products—including hemp-derived THC beverages, edibles, tinctures, and full-spectrum CBD products—for an additional 29 days. It does not, however, create any new federal regulatory framework for those products, and it does not preempt or override state-level restrictions that have been enacted independently.
- Competing Legislative Proposals
The one-month delay is a stopgap, not a solution. Multiple competing bills and proposals are pending in Congress, reflecting a range of approaches:
- Longer delays or repeal: Some proposals would delay the new definition by two years or repeal it entirely.
- Higher THC thresholds: The Lawful Hemp Protection Act, a bipartisan discussion draft, would raise the federal plant-level threshold to 1% total delta-9 THC on a dry-weight basis and shift to final-form product testing.
- Federal regulatory frameworks: The Lawful Hemp Protection Act and other proposals would establish age restrictions (with a minimum purchase age of 21), labeling and packaging requirements, product warnings, maximum cannabinoid amounts to be set through agency rulemaking, testing requirements, and federal oversight—potentially through the FDA or a new regulatory structure.
- State-deference approaches: Other proposals would defer to state definitions, allowing states to set their own hemp-product standards within a federal floor.
- Tax-and-regulate models: Other legislation is seeking to keep hemp THC beverages legal while taxing and regulating them like alcohol.
None of these proposals have been enacted, and it remains to be seen which approach, if any, can attract sufficient support during the compressed December lame-duck session.
The brief 29-day reprieve, if enacted, provides additional time but does not eliminate the significant uncertainty facing the hemp and cannabis industries. Businesses should continue monitoring federal and state developments, evaluate how the staggered effective dates may affect their products and operations, and review testing, sourcing, inventory, distribution, and contractual arrangements. With Congress still weighing regulation against prohibition, companies should prepare for multiple outcomes when the extension expires in December.